Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function Genotype: a Validation Study in Patients With Stable Coronary Artery Disease

Trial Profile

Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function Genotype: a Validation Study in Patients With Stable Coronary Artery Disease

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 25 Jun 2018

At a glance

  • Drugs Prasugrel (Primary) ; Ticagrelor (Primary)
  • Indications Coronary artery disease
  • Focus Pharmacodynamics
  • Most Recent Events

    • 14 Jun 2018 Status changed from not yet recruiting to recruiting.
    • 04 May 2018 Planned initiation date changed from 1 Apr 2018 to 1 May 2018.
    • 10 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top